U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497087) titled 'A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis' on March 23.
Brief Summary: Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well...